Citations

Clear

959 citation(s) found for "Service, F J".

Longitudinal Retinal Changes in MOGAD
Oertel, Frederike Cosima , Sotirchos, Elias S. , Zimmermann, Hanna , Motamedi, Seyedamirhosein , Specovius, Svenja , Asseyer, Eva Susanna, Chien, Claudia , Cook, Lawrence J. , Vasileiou, Eleni S. , Filippatou, Angeliki , D’Cunha, Anitha , Pittock, Sean J. , Bhatti, M. Tariq , Rommer, Paulus , Bsteh, Gabriel , Zrzavy, Tobias , Kuempfel, Tania, Aktaş, Orhan , Ringelstein, Marius , Ayzenberg, Ilya , Pakeerathan, Thivya , Knier, Benjamin , Asgari, Nasrin , Soelberg, Kerstin , Marignier, Romain , Tilikete, Caroline , Calvo, Álvaro Cobo, Villoslada, Pablo , Sánchez‐Dalmau, Bernardo , Green, Ari , Brandt, Alexander U. , Chen, John , Paul, Friedemann , Palace, Jacqueline , Chen, John J. , Asseyer, Susanna , Huda, Saif , Zimmermann, Hanna G , Vasileiou, Eleni , Calabresi, Peter A , Pandit, Lekha , Zéphir, Hélène , Pittock, S J , Bsteh, Gabriel , Zrzavy, Tobias , Kuempfel, Tania , Ringelstein, Marius , Albrecht, Philipp , Knier, Benjamin , Aly, Lilian , Marignier, Romain , Villoslada, Pablo , Brandt, Alexander U , Paul, Friedemann , Chen, John J , Sotirchos, Elias S , Oertel, Frederike C , Palace, Jacqueline , Rommer, Paulus S , Filippatou, Angeliki G , Cook, Lawrence J , Calabresi, Peter A. , Saidha, Shiv , Pandit, Lekha , Outteryck, Olivier , Flanagan, Eoin P. , Kümpfel, Tania , Martínez‐Lapiscina, Elena H. , Llufriú, Sara , Yeaman, Michael R , Smith, Terry J. , Havla, Joachim

Mayo Clinic

Annals of Neurology | June 15, 2022 | Volume: 92 | Issue: 3 | Pages: 476-485

10.1002/ana.26440 | PMID 35703428 Get It

ObjectivePatients with myelin oligodendrocyte glycoprotein antibody (MOG‐IgG)‐associated disease (MOGAD) suffer from severe optic neuritis (ON) leading to retinal neuro‐axonal loss, which can be quantified by optical coherence tomography (OCT). We assessed whether ON‐independent retinal atrophy can be detected in MOGAD.MethodsEighty patients with MOGAD and 139 healthy controls (HCs) were included. OCT data was acquired with (1) Spectralis spectral domain OCT (MOGAD: N = 66 and HCs: N = 103) and (2) Cirrus high‐definition OCT (MOGAD: N = 14 and HCs: N = 36). Macular combined ganglion cell and inner plexiform layer (GCIPL) and peripapillary retinal nerve fiber layer (pRNFL) were quantified.ResultsAt baseline, GCIPL and pRNFL were lower in MOGAD eyes with a history of ON (MOGAD‐ON) compared with MOGAD eyes without a history of ON (MOGAD‐NON) and HCs (p < 0.001). MOGAD‐NON eyes had lower GCIPL volume compared to HCs (p < 0.001) in the Spectralis, but not in the Cirrus cohort. Longitudinally (follow‐up up to 3 years), MOGAD‐ON with ON within the last 6–12 months before baseline exhibited greater pRNFL thinning than MOGAD‐ON with an ON greater than 12 months ago (p < 0.001). The overall MOGAD cohort did not exhibit faster GCIPL thinning compared with the HC cohort.InterpretationOur study suggests the absence of attack‐independent retinal damage in patients with MOGAD. Yet, ongoing neuroaxonal damage or edema resolution seems to occur for up to 12 months after ON, which is longer than what has been reported with other ON forms. These findings support that the pathomechanisms underlying optic nerve involvement and the evolution of OCT retinal changes after ON is distinct in patients with MOGAD. ANN NEUROL 2022;92:476–485
Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis
Robin, Marie , Wreede, Liesbeth C. de , Padron, Eric , Bakunina, Katerina , Fenaux, Pierre , Köster, Linda, Nazha, Aziz , Rampal, Raajit K. , Sockel, Katja , Gagelmann, Nico , Eikema, Dirk‐Jan, Potter, Victoria , Killick, Sally , Legrand, Faézeh, Broom, Angus, Garcia‐Manero, Guillermo , Rizzoli, Vittorio, Hayden, Patrick , Patnaik, Mrinal M. , Yakoub‐Agha, Ibrahim , Itzykson, Raphaël , de Wreede, Liesbeth C , Komrokji, Rami S , Gagelmann, Nico , Finke, Jürgen , Solary, Eric , Patnaik, Mrinal , Yakoub-Agha, Ibrahim , Itzykson, Raphael , Robin, Marie , Beelen, Dietrich Wilhelm , Komrokji, Rami S. , Radujkovic, Aleksandar , Solary, Éric , Onida, Francesco

Mayo Clinic

Blood | June 6, 2022 | Volume: 140 | Issue: 12 | Pages: 1408-1418

10.1182/blood.2021015173 | PMID 35667047 Get It

Abstract To determine the survival benefit of allogeneic hematopoietic cell transplantation (allo-HCT) in chronic myelomonocytic leukemias (CMML), we assembled a retrospective cohort of CMML patients 18-70 years old diagnosed between 2000 and 2014 from an international CMML dataset (n = 730) and the EBMT registry (n = 384). The prognostic impact of allo-HCT was analyzed through univariable and multivariable time-dependent models and with a multistate model, accounting for age, sex, CMML prognostic scoring system (low or intermediate-1 grouped as lower-risk, intermediate-2 or high as higher-risk) at diagnosis, and AML transformation. In univariable analysis, lower-risk CMMLs had a 5-year overall survival (OS) of 20% with allo-HCT vs 42% without allo-HCT (P &lt; .001). In higher-risk patients, 5-year OS was 27% with allo-HCT vs 15% without allo-HCT (P = .13). With multistate models, performing allo-HCT before AML transformation reduced OS in patients with lower-risk CMML, and a survival benefit was predicted for men with higher-risk CMML. In a multivariable analysis of lower-risk patients, performing allo-HCT before transformation to AML significantly increased the risk of death within 2 years of transplantation (hazard ratio [HR], 3.19; P &lt; .001), with no significant change in long-term survival beyond this time point (HR, 0.98; P = .92). In higher-risk patients, allo-HCT significantly increased the risk of death in the first 2 years after transplant (HR 1.46; P = .01) but not beyond (HR, 0.60; P = .09). Performing allo-HCT before AML transformation decreases life expectancy in lower-risk patients but may be considered in higher-risk patients.
14 Impact of epilepsy or seizures on outcomes following takotsubo cardiomyopathy
Sawatari, Hiroyuki , Wafa, Syed Emir Irfan , Padmanabhan, Deepak , Ahmed, Raheel , Deshpande, Saurabh , Khanji, Mohammed Y , Somers, Virend K. , Chahal, C. Anwar A.

Mayo Clinic

ACHD/Valve disease/Pericardial disease/Cardiomyopathy | June 6, 2022 | Volume: No volume available | Issue: No issue available | Pages: A11.2-A12

10.1136/heartjnl-2022-bcs.14 Get It

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
Martin, Thomas G. , Usmani, Saad Z. , Berdeja, Jesús G. , Agha, Mounzer , Cohen, Adam D. , Hari, Parameswaran , Avigan, David , Deol, Abhinav , Htut, Myo , Lesokhin, Alexander M. , Munshi, Nikhil C. , O’Donnell, Elizabeth , Stewart, A. Keith , Schecter, Jordan M. , Goldberg, Jenna D., Jackson, Carolyn C. , Yeh, Tzu‐Min, Banerjee, Arnob , Allred, Alicia J., Zudaire, Enrique, Deraedt, William , Olyslager, Yunsi, Zhou, Changwei, Pacaud, Lida , Lin, Yi , Jakubowiak, Andrzej , Lin, Yi , Jagannath, Sundar , Lesokhin, Alexander M , Cohen, Adam D , Hari, Parameswaran , Berdeja, Jesús G , Usmani, Saad , Goldberg, Jenna D., Madduri, Deepu , Jakubowiak, Andrzej , Jagannath, Sundar

Mayo Clinic

Journal of Clinical Oncology | June 4, 2022 | Volume: 41 | Issue: 6 | Pages: 1265-1274

10.1200/jco.22.00842 | PMID 35658469 Get It

PURPOSE CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory multiple myeloma, yielded early, deep, and durable responses at 12 months. Here, we present updated results 2 years after last patient in (median follow-up [MFU] approximately 28 months), including analyses of high-risk patient subgroups. METHODS Eligible patients had relapsed/refractory multiple myeloma, had received ≥ 3 prior lines of therapy or were double refractory to a proteasome inhibitor and immunomodulatory drug and had received prior proteasome inhibitor, immunomodulatory drug, and anti-CD38 therapy. Patients received a single cilta-cel infusion 5-7 days after lymphodepletion. Responses were assessed by an independent review committee. RESULTS At a MFU of 27.7 months (N = 97), the overall response rate was 97.9% (95% CI, 92.7 to 99.7); 82.5% (95% CI, 73.4 to 89.4) of patients achieved a stringent complete response. Median duration of response was not estimable. Median progression-free survival (PFS) and overall survival (OS) were not reached; 27-month PFS and OS rates were 54.9% (95% CI, 44.0 to 64.6) and 70.4% (95% CI, 60.1 to 78.6), respectively. Overall response rates were high across all subgroups (95.1%-100%). Duration of response, PFS, and/or OS were shorter in patients with high-risk cytogenetics, International Staging System stage III, high tumor burden, or plasmacytomas. The safety profile was manageable with no new cilta-cel–related cytokine release syndrome and one new case of parkinsonism (day 914 after cilta-cel) since the last report. CONCLUSION At approximately 28 months MFU, patients treated with cilta-cel maintained deep and durable responses, observed in both standard and high-risk subgroups. The risk/benefit profile of cilta-cel remained favorable with longer follow-up.
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Campo, Elı́as , Jaffe, Elaine S. , Cook, James R. , Quintanilla‐Martínez, Leticia , Brousset, Pierre , Cerroni, Lorenzo , Dirnhofer, Stefan , Friedberg, Jonathan W. , King, Rebecca L., Miguel, Jesús F. San , Seymour, John F. , Advani, Ranjana H. , Ansell, Stephen M. , Au, Wing-Yan, Bergsagel, Leif, Cohen, Jeffrey I. , d’Amore, Francesco, Ghobrial, Irene M. , Kim, Won-Seog, Kumar, Shaji , LaCasce, Ann S. , Laurent, Camille , Lenz, Georg, Leonard, John P. , Link, Michael P., López‐Guillermo, Armando , Mateos, María‐Victoria , Melnick, Ari , Nakamura, Shigeo, Narbaitz, Marina, Pavlovsky, Astrid , Pro, Barbara, Sander, Birgitta , Smith, Sonali M. , Staudt, Louis M. , Thieblemont, Catherine, Tousseyn, Thomas , Wilson, Wyndham H., Yoshino, Tadashi, Dreyling, Martin , Winter, Jane N., Bergsagel, P. Leif , Dirnhofer, S , Bergsagel, P. Leif , Brousset, Pierre , Dogan, Ahmet , Feldman, Andrew L , Ghia, Paolo , Salles, Gilles A , San-Miguel, Jesus , Seymour, John F , Treon, Steven , Vose, Julie , Zucca, Emanuele , Barrionuevo, Carlos , Davies, Andrew , Falini, Brunangelo , Ghobrial, Irene M , Goodlad, John R , Gribben, John G. , Hsi, Eric D , Kahl, Brad S , Kumar, Shaji K , LaCasce, Ann Steward , Mateos, María-Victoria , Macintyre, Elizabeth , Melnick, Ari , Morschhauser, Franck , Pileri, Stefano , Piris, Miguel , Rajkumar, Vincent, Shipp, Margaret Ann , Smith, Sonali M , Zinzani, Pier Luigi , Dreyling, Martin , Scott, David W , Zelenetz, Andrew D , Jaffe, Elaine S , Campo, Elías , Advani, Ranjana H , Quintanilla-Martinez, Leticia , Swerdlow, Steven H. , Anderson, Kenneth C. , Leval, Laurence de , Doǧan, Ahmet , Feldman, Andrew L. , Fend, Falko , Gaulard, Philippe , Ghia, Paolo , Horwitz, Steven M. , Salles, Gilles , Treon, Steven P. , Vose, Julie M. , Zucca, Emanuele , Chan, Wing C., Davies, Andrew , Falini, Brunangelo , Hsi, Eric D. , Kahl, Brad S. , Kim, Won Seog , Lenz, Georg , Macintyre, Elizabeth , Morschhauser, Franck , Pileri, Stefano , Piris, Miguel Á. , Rajkumar, S. Vincent , Rosen, Steven T. , Sehn, Laurie H. , Thiéblemont, Catherine , Wilson, Wyndham H. , Yoshino, Tadashi, Zinzani, Pier Luigi , Scott, David W. , Winter, Jane N. , Zelenetz, Andrew D.

Mayo Clinic

Blood | June 2, 2022 | Volume: 140 | Issue: 11 | Pages: 1229-1253

10.1182/blood.2022015851 | PMID 35653592 Get It

Abstract Since the publication of the Revised European-American Classification of Lymphoid Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have been generated through iterative international efforts to achieve broad consensus among hematopathologists, geneticists, molecular scientists, and clinicians. Significant progress has recently been made in the characterization of malignancies of the immune system, with many new insights provided by genomic studies. They have led to this proposal. We have followed the same process that was successfully used for the third and fourth editions of the World Health Organization Classification of Hematologic Neoplasms. The definition, recommended studies, and criteria for the diagnosis of many entities have been extensively refined. Some categories considered provisional have now been upgraded to definite entities. Terminology for some diseases has been revised to adapt nomenclature to the current knowledge of their biology, but these modifications have been restricted to well-justified situations. Major findings from recent genomic studies have impacted the conceptual framework and diagnostic criteria for many disease entities. These changes will have an impact on optimal clinical management. The conclusions of this work are summarized in this report as the proposed International Consensus Classification of mature lymphoid, histiocytic, and dendritic cell tumors.
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
Davies, Faith E. , Pawlyn, Charlotte , Usmani, Saad Z. , Miguel, Jesús F. San , Boyle, Eileen M. , Corre, Jill , Auclair, Daniel , Cho, Hearn Jay , Sonneveld, Pieter , Stewart, A. Keith , Bergsagel, P. Leif , Kaiser, Martin , Morgan, Kathryn E., Ghobrial, Irene M. , Orlowski, Robert Z. , Caers, Joseph, Chari, Ajai , Walker, Brian A. , Kumar, Shaji , Costa, Luciano J. , Bergsagel, P. Leif , San-Miguel, Jesus , Boyle, Eileen M , Corre, Jill , Cho, Hearn Jay , Kaiser, Martin F , Keats, Jonathan J , Mikhael, Joseph R , Orlowski, Robert Z. , Landgren, C Ola , Gay, Francesca , Chng, Wee Joo , Chari, Ajai , Walker, Brian A , Kumar, Shaji K , Costa, Luciano J , Anderson, Kenneth C , Morgan, Gareth J , Davies, Faith E , Ghobrial, Irene M , Pawlyn, Charlotte , Usmani, Saad , Einsele, Hermann , Lonial, Sagar , Weisel, Katja C , Keats, Jonathan J. , Mıkhael, Joseph , Landgren, Ola , Gay, Francesca , Chng, Wee Joo , Anderson, Kenneth C. , Morgan, Gareth J.

Mayo Clinic

Blood Cancer Discovery | June 2, 2022 | Volume: 3 | Issue: 4 | Pages: 273-284

10.1158/2643-3230.bcd-21-0205 | PMID 35653112 Get It

Summary: The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in clinical outcomes, with a proportion of patients not benefiting from current approaches and continuing to have a poor prognosis. A significant proportion of the variability in outcome can be predicted on the basis of clinical and biochemical parameters and tumor-acquired genetic variants, allowing for risk stratification and a more personalized approach to therapy. This article discusses the principles that can enable the rational and effective development of therapeutic approaches for high-risk multiple myeloma.
Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study
Heiblig, Maël , Ferrada, Marcela A. , Koster, Matthew T., Barba, Thomas , Gerfaud‐Valentin, Mathieu , Mékinian, A. , Coelho, Henrique , Fossard, Gaëlle , Barraco, Fiorenza , Galicier, Lionel , Bienvenu, Boris , Hirsch, Pierre , Vial, Guillaume , Boutin, Anne Blandine, Guenno, G. Le , Bigot, Adrien , Kermani, Tanaz A. , Grayson, Peter C. , Beck, David B. , Fenaux, Pierre , Sujobert, Pierre , Mékinian, Arsène , Galland, Joris , Le Guenno, Guillaume , Bigot, Adrien , Jamilloux, Yvan , Heiblig, Mael , Ferrada, Marcela A , Koster, Matthew, Warrington, Kenneth J. , Patel, Bhavisha A.

Mayo Clinic

Blood | May 24, 2022 | Volume: 140 | Issue: 8 | Pages: 927-931

10.1182/blood.2022016642 | PMID 35609174 Get It

VEXAS syndrome (vacuoles in myeloid progenitors, E1 ubiquitin activating enzyme, X-linked, autoinflammatory manifestations and somatic) is an autoinflammatory condition caused by somatically acquired UBA1 mutations. Heiblig et al report on an international retrospective analysis of 30 patients with VEXAS syndrome treated with different Janus kinase (JAK) inhibitors, finding encouraging evidence supporting the use of the JAK1/2 inhibitor ruxolitinib with clinical remissions and reductions in steroid use seen in the majority of patients.
Catheter ablation for atrial fibrillation in the elderly >75 years old: Systematic review and meta‐analysis
Prasitlumkum, Narut , Tokavanich, Nithi , Cheungpasitporn, Wisit, Kewcharoen, Jakrin , Chokesuwattanaskul, Ronpichai , Akoum, Nazem , Bunch, T. Jared , Navaravong, Leenhapong , Cheungpasitporn, Wisit , Kewcharoen, Jakrin , Chokesuwattanaskul, Ronpichai , Akoum, Nazem , Navaravong, Leenhapong , Cheungpasitporn, Wisit , Prasitlumkum, Narut , Trongtorsak, Angkawipa

Mayo Clinic

Journal of Cardiovascular Electrophysiology | May 20, 2022 | Volume: 33 | Issue: 7 | Pages: 1435-1449

10.1111/jce.15549 | PMID 35589557 Get It

AbstractIntroductionAtrial fibrillation (AF) ablation is increasingly performed worldwide. As comfort with AF ablation increases, the procedure is increasingly used in patients that are older and in those with more comorbidities. However, it is not well established whether AF ablation in the elderly, especially those >75 years old, has comparable safety and efficacy to younger populations.ObjectiveTo compare the efficacy and safety profiles in patients older than 75 years undergoing AF ablation with younger patients.MethodsDatabases from EMBASE, Medline, PubMed, and Cochrane, were searched from inception through September 2021. Studies that compared the success rates in AF catheter ablation and all complications rates between patients who were older vs under 75 years were included. Effect estimates from the individual studies were extracted and combined using random effect, generic inverse variance method of DerSimonian and Laird.ResultsTwenty‐seven observational studies were included in the analysis consisting of 363,542 patients who underwent AF ablation. Comparing patients older than 75 years old to younger patients, there was no difference in the success of ablation rates between elderly and younger patients (pooled OR 0.85: 95% CI:0.69–1.05, p = .131). On the other hand, AF ablation in the elderly was associated with higher complication rates (pooled OR 1.42: 95% CI:1.21–1.68, p < .001).ConclusionAs AF ablation is expanded to elderly populations, our study found that AF ablation success rates were similar in both elderly and younger patients. However, older patients experience higher rates of complications that should be considered when offering the procedure and as a means to improve outcomes with future innovations.
Targeting HER2 mutant advanced biliary tract cancers with neratinib: results from the SUMMIT ‘basket’ trial
Harding, James J. , Shah, Ronak , Murphy, Jessica, Cleary, James M. , Shapiro, Geoffrey I. , Moreno, Víctor , Loi, Sherene , Spanggaard, Iben , Park, Haeseong , Stemmer, Salomon M. , DiPrimeo, Daniel, Savin, Casey , Selçuklu, S. Duygu , Berger, Michael , Moreno, Victor , Loi, Sherene , Shapiro, Geoffrey I , Harding, James J , Piha‐Paul, Sarina A. , Quinn, David I , Braña, Irene , Borad, Mitesh J. , Ford, James M. , Arnedos, Mónica , Fouchardière, Christelle de la , Fountzilas, Christos , Zhang, Jie , Eli, Lisa D. , Meric‐Bernstam, Funda , Jhaveri, Komal , Solit, David B. , Abou‐Alfa, Ghassan K.

Mayo Clinic

No container title available | May 11, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1576467/v1 Get It

Abstract HER2 mutations are infrequent genomic events in biliary tract cancers (BTCs). Neratinib, an irreversible, pan-HER, oral tyrosine kinase inhibitor, interferes with constitutive receptor kinase activation and has activity in HER2-mutant tumours. SUMMIT is an open-label, single-arm, multi-cohort, phase 2, ‘basket’ trial of neratinib in patients with solid tumours harbouring oncogenic HER2 somatic mutations (NCT01953926). The primary objective of the BTC cohort was objective response rate (ORR). Among 25 treatment-refractory patients (11 cholangiocarcinoma, 10 gallbladder, 4 ampullary cancers), the ORR was 16%. The most common HER2 mutations were S310F (n = 11; 48%) and V777L (n = 4; 17%). Outcomes appeared worse for ampullary tumours or those with co-occurring oncogenic TP53 and CDKN2A alterations. Loss of amplified HER2 S310F and acquisition of multiple previously undetected oncogenic co-mutations were identified at progression in one responder. Neratinib demonstrated anti-tumour activity in patients with refractory BTC harbouring HER2 mutations. Future studies of rational combinations are warranted.
Peri-intubation Cardiovascular Collapse in Patients Who Are Critically Ill: Insights from the INTUBE Study
Russotto, Vincenzo , Parotto, Matteo , Bauer, Philippe R. , Camporota, Luigi , Putensen, Christian , Higgs, A. , Pesenti, Antonio, Valsecchi, Maria Grazia , Fumagalli, Roberto , Laffey, John G. , Brewster, David , Mazlan, Mohd Zulfakar , Rahmani, Lua S. , Bauer, Philippe R , Bellani, Giacomo , Laffey, John G , Lascarrou, Jean-Baptiste , Tassistro, Elena , Myatra, Sheila Nainan , Antolini, Laura , Szuldrzynski, Konstanty S. , Pelosi, Paolo , Sorbello, Massimiliano , Greif, Robert , Pesenti, Antonio, Foti, Giuseppe

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 10, 2022 | Volume: 206 | Issue: 4 | Pages: 449-458

10.1164/rccm.202111-2575oc | PMID 35536310 Get It

Abstract Rationale Cardiovascular instability/collapse is a common peri-intubation event in patients who are critically ill. Objectives To identify potentially modifiable variables associated with peri-intubation cardiovascular instability/collapse (i.e., systolic arterial pressure &lt;65 mm Hg [once] or &lt;90 mm Hg for &gt;30 minutes; new/increased vasopressor requirement; fluid bolus &gt;15 ml/kg, or cardiac arrest). Methods INTUBE (International Observational Study to Understand the Impact and Best Practices of Airway Management In Critically Ill Patients) was a multicenter prospective cohort study of patients who were critically ill and undergoing tracheal intubation in a convenience sample of 197 sites from 29 countries across five continents from October 1, 2018, to July 31, 2019. Measurements and Main Results A total of 2,760 patients were included in this analysis. Peri-intubation cardiovascular instability/collapse occurred in 1,199 out of 2,760 patients (43.4%). Variables associated with this event were older age (odds ratio [OR], 1.02; 95% confidence interval [CI], 1.02–1.03), higher heart rate (OR, 1.008; 95% CI, 1.004–1.012), lower systolic blood pressure (OR, 0.98; 95% CI, 0.98–0.99), lower oxygen saturation as measured by pulse oximetry/Fi O2 before induction (OR, 0.998; 95% CI, 0.997–0.999), and the use of propofol as an induction agent (OR, 1.28; 95% CI, 1.05–1.57). Patients with peri-intubation cardiovascular instability/collapse were at a higher risk of ICU mortality with an adjusted OR of 2.47 (95% CI, 1.72–3.55), P &lt; 0.001. The inverse probability of treatment weighting method identified the use of propofol as the only factor independently associated with cardiovascular instability/collapse (OR, 1.23; 95% CI, 1.02–1.49). When administered before induction, vasopressors (OR, 1.33; 95% CI, 0.84–2.11) or fluid boluses (OR, 1.17; 95% CI, 0.96–1.44) did not reduce the incidence of cardiovascular instability/collapse. Conclusions Peri-intubation cardiovascular instability/collapse was associated with an increased risk of both ICU and 28-day mortality. The use of propofol for induction was identified as a modifiable intervention significantly associated with cardiovascular instability/collapse. Clinical trial registered with clinicaltrials.gov (NCT03616054).